Order Article Reprints

Lin Z-Y, Yeh M-L, Liang P-C, Hsu P-Y, Huang C-F, Huang J-F, Dai C-Y, Yu M-L, Chuang W-L. Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy. Cancers. 2023; 15(20):5097. https://doi.org/10.3390/cancers15205097

Lin, Zu-Yau, Ming-Lun Yeh, Po-Cheng Liang, Po-Yao Hsu, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Ming-Lung Yu, and Wan-Long Chuang. 2023. "Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy" Cancers 15, no. 20: 5097. https://doi.org/10.3390/cancers15205097

Lin, Z.-Y., Yeh, M.-L., Liang, P.-C., Hsu, P.-Y., Huang, C.-F., Huang, J.-F., Dai, C.-Y., Yu, M.-L., & Chuang, W.-L. (2023). Dose Consideration of Lenvatinib’s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy. Cancers, 15(20), 5097. https://doi.org/10.3390/cancers15205097